Harnessing the CD1 restricted T cell response for leukemia adoptive immunotherapy. (August 2017)

• Record Type: Journal Article
• Authors: Consonni, Michela; de Lalla, Claudia; Bigi, Alessandra; Dellabona, Paolo; Casorati, Giulia
• Is Part Of: Cytokine & growth factor reviews. Volume 36(2017)
• Page Start: 117
• Page End: 123
• Publication Date: 2017-08
• Subjects: MHC major histocompatibility complex -- ACT adoptive cell therapy -- DC Dendritic cells -- AML T-ALL. B-ALL -- mLPA methyl-lysophosphatidic acid -- HSCT hematopoietic stem cell transplantation -- GVL graft versus leukemia -- GVHD graft versus host disease -- iNKT invariant natural killer T; CD1 molecules -- TCR grafting -- Lipid antigen -- Adoptive immunotherapy -- Engineered T cells -- Acute leukemia; Cytokines -- Periodicals; 571.84
• DOI: 10.1016/j.cytogfr.2017.06.007
• Languages: English
• ISSNs: 1359-6101

Abstract

Abstract: Disease recurrence following chemotherapy and allogeneic hematopoietic cell transplantation is the major unmet clinical need of acute leukemia. Adoptive cell therapy (ACT) with allogeneic T lymphocytes can control recurrences at the cost of inducing detrimental GVHD. Targeting T cell recognition on leukemia cells is therefore needed to overcome the problem and ensure safe and durable disease remission. In this review, we discuss adoptive cells therapy based on CD1-restricted T cells specific for tumor associated self-lipid antigens. CD1 molecules are identical in every individual and expressed essentially on mature hematopoietic cells and leukemia blasts, but not by parenchymatous cells, while lipid antigens are enriched in malignant cells and unlike to mutate upon immune-mediated selective pressure. Redirecting T cells against self-lipids presented by CD1 molecules can thus provide an appealing cell therapy strategy for acute leukemia that is patient-unrestricted and can minimize risks for GVHD, implying potential prognostic improvement for this cancer.